CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.83
+0.58 (7.03%)
At close: Aug 1, 2025, 4:00 PM
8.64
-0.19 (-2.15%)
After-hours: Aug 1, 2025, 7:56 PM EDT
Chimerix Revenue
CervoMed had revenue of $1.92M in the quarter ending March 31, 2025, a decrease of -18.31%. This brings the company's revenue in the last twelve months to $9.31M, up 15.14% year-over-year. In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth.
Revenue (ttm)
$9.31M
Revenue Growth
+15.14%
P/S Ratio
8.26
Revenue / Employee
$620,548
Employees
15
Market Cap
76.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
Dec 31, 2023 | 7.14M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 5 days ago - CervoMed's Dementia Data Show Slowed Disease Progression - Benzinga
- 5 days ago - CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration - GlobeNewsWire
- 25 days ago - CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025 - GlobeNewsWire
- 2 months ago - CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 4 months ago - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - GlobeNewsWire
- 4 months ago - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
- 5 months ago - CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - GlobeNewsWire